JPWO2022004760A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022004760A5
JPWO2022004760A5 JP2022534067A JP2022534067A JPWO2022004760A5 JP WO2022004760 A5 JPWO2022004760 A5 JP WO2022004760A5 JP 2022534067 A JP2022534067 A JP 2022534067A JP 2022534067 A JP2022534067 A JP 2022534067A JP WO2022004760 A5 JPWO2022004760 A5 JP WO2022004760A5
Authority
JP
Japan
Prior art keywords
tumor
antibody
days
oxaliplatin
administration group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534067A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022004760A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/024651 external-priority patent/WO2022004760A1/ja
Publication of JPWO2022004760A1 publication Critical patent/JPWO2022004760A1/ja
Publication of JPWO2022004760A5 publication Critical patent/JPWO2022004760A5/ja
Pending legal-status Critical Current

Links

JP2022534067A 2020-06-30 2021-06-30 Pending JPWO2022004760A1 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020112259 2020-06-30
JP2020196405 2020-11-26
PCT/JP2021/024651 WO2022004760A1 (ja) 2020-06-30 2021-06-30 抗ｃｃｒ８抗体と化学療法剤の併用

Publications (2)

Publication Number Publication Date
JPWO2022004760A1 JPWO2022004760A1 (https=) 2022-01-06
JPWO2022004760A5 true JPWO2022004760A5 (https=) 2023-03-16

Family

ID=79316496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534067A Pending JPWO2022004760A1 (https=) 2020-06-30 2021-06-30

Country Status (4)

Country Link
US (1) US20230256092A1 (https=)
EP (1) EP4173636A4 (https=)
JP (1) JPWO2022004760A1 (https=)
WO (1) WO2022004760A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
JP2024522360A (ja) 2021-06-04 2024-06-18 アムジエン・インコーポレーテツド 抗ｃｃｒ８抗体及びその使用
CN116789820A (zh) * 2022-03-18 2023-09-22 北京天诺健成医药科技有限公司 一种新型免疫调节剂的开发和应用
US20250243287A1 (en) * 2022-04-07 2025-07-31 Shenghe (China) Biopharmaceutical Co., Ltd. Anti-ccr8 antibody or antigen-binding fragment thereof
JP2025537137A (ja) * 2022-11-04 2025-11-14 ギリアード サイエンシーズ， インコーポレイテッド 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
AU2024247601A1 (en) * 2023-03-28 2025-10-23 Nb Health Laboratory Co., Ltd. Antibody, nucleic acid, cell and drug
TW202529804A (zh) 2023-10-06 2025-08-01 美商安進公司 用於癌症治療的組合療法
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
CN119798438B (zh) * 2023-12-29 2025-11-18 广东东阳光药业股份有限公司 一种抗ccr8单克隆抗体及其应用
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214973B1 (en) 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
EP3255060A1 (en) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PT2769737T (pt) 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
AU2014309199B2 (en) 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
JP2017507900A (ja) * 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
PL3102605T3 (pl) 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
DK3334457T3 (da) * 2015-08-10 2020-09-21 Pepmab B V Humaniserede anti-CCR7-receptorantistoffer
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
ES2863412T3 (es) 2017-03-29 2021-10-11 Shionogi & Co Composición farmacéutica para el tratamiento del cáncer
WO2019157098A1 (en) 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
CN110835374A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8×ctla-4双特异性抗体及其应用
WO2020138489A1 (ja) * 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體

Similar Documents

Publication Publication Date Title
JPWO2022004760A5 (https=)
US10766943B2 (en) Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
ES2986343T3 (es) Anticuerpos contra CLAUDINA-6 y métodos para tratar el cáncer
UA128825C2 (uk) Гетеродимерні антитіла, що зв'язують enpp3 та cd3
UA126964C2 (uk) Конструкція біспецифічного антитіла, що зв'язується з дпб3 (dll3) і кд3 (cd3)
EP3360893B1 (en) High-affinity and soluble pdl-1 molecule
UA111612C2 (uk) Домени, які зв'язуються з деімунізованою сироваткою, і їхнє застосування для збільшення часу напівжиття в сироватці
EP3746103A1 (en) Engineered proteins to enhance sensitivity of a cell to il-2
Saito et al. CAR-T cell therapy in AML: recent progress and future perspectives
Getts et al. Synthetic T cell receptor-based lymphocytes for cancer therapy
JP2018016619A (ja) Ａｌｌｅｒｇｉｎ−１アンタゴニストによるがん免疫増強剤
CN118240093A (zh) 一种靶向her2与egfr的三特异性t细胞衔接器及其应用
CN112521513A (zh) 一种靶向cd19的嵌合抗原受体（car）及其应用
IL324321A (en) Multi-receptor natural killer cells
WO2017162185A1 (zh) 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物
ES2936075T3 (es) Activador de células T reguladoras, y uso del mismo
Interdonato et al. BL-01, an Fc-bearing, tetravalent CD20× CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo
US20230040568A1 (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
CN116041539B (zh) Il-2突变体免疫缀合物
CN119424608A (zh) Star及包含其的免疫细胞在治疗和预防肿瘤中应用
CN112457416B (zh) 一种靶向bcma的嵌合抗原受体(car)及其应用
WO2020077180A1 (en) Treatment of immunosuppressed subjects
Smyth et al. Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin‐monoclonal antibody conjugates
CN111093703A (zh) 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途
Jenkins Generating Protective Cancer Immunity by Allowing Nature to Lead the Way